Filters:
Investigator: Jeffrey Rothstein3 Projects | 1 Researchers | $545,991 Invested
2024
Johns Hopkins University
Jeffrey Rothstein, MD, PhD
Mitigating TDP-43 loss of function and disease initiation in FTD thru repair of the Nuclear Pore and CHMP7/ESCRT3 dysfunction.
2013
Johns Hopkins University
Jeffrey Rothstein, MD, PhD
Biomarker assay development to accompany antisense oligonucleotide therapeutic for mutant C9orf72-positive FTD patients
2012
Johns Hopkins University
Jeffrey Rothstein, MD, PhD
Development of Antisense therapy and Therapeutic biomarker for C9orf72 FTD/ALS mutation patients